carbidopa, levodopa drug combination has been researched along with reserpine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eller, RV; Gash, DM; Greenamyre, JT; Kurlan, R; Ovadia, A; Zhang, Z | 1 |
| Guerrero, MF; López, JL; Olaya, MDP; Vergel, NE; Viña, MD | 1 |
2 other study(ies) available for carbidopa, levodopa drug combination and reserpine
| Article | Year |
|---|---|
Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetamides; Analysis of Variance; Animals; Anticonvulsants; Antiparkinson Agents; Brain; Carbidopa; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca mulatta; Male; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reserpine; Time Factors | 1994 |
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Topics: Animals; Antiparkinson Agents; Carbidopa; Catalepsy; Coumarins; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Haloperidol; Levodopa; Locomotion; Male; Mice; Mice, Inbred ICR; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Reserpine | 2019 |